Aker BioMarine reports mixed financial results for the second quarter, with outlets describing both revenue movement and ongoing demand for its krill-based products. One report says Q2 revenue rises about 5%, attributing the improvement to sustained krill oil demand. Another report describes Q2 2026 as weaker overall, noting that revenue falls short even as krill growth remains a bright spot. Taken together, the coverage indicates that underlying demand for krill oil continues to support performance, but company or market expectations are not fully met. The reports also imply that growth related to krill operations or capacity is proceeding, while revenue figures do not align with targets or forecasts referenced by the media. Overall, Aker BioMarine’s quarter is characterized by continued strength in krill-linked metrics alongside a revenue outcome that is described differently across sources—one emphasizing a modest increase, the other highlighting a miss versus expectations.